Mario Guslandi

San Raffaele University of Rome

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

A. Tittobello

University of Milan

Pier Alberto Testoni

IRCCS Ospedale San Raffaele

E. Masci

Aziende Socio Sanitarie Territoriale Nord Milano

M. Sorghi

Vita-Salute San Raffaele University

Sandro Passaretti

IRCCS Ospedale San Raffaele

P.A. Testoni

University of Milan

Elena Ballarín

Vall d'Hebron Institut de Recerca

L. Fanti

Vita-Salute San Raffaele University

Lorella Fanti

Vita-Salute San Raffaele University

M Cambielli

Società Italiana di Medicina Generale

Cooperative Institutions

University of Milan

Istituti di Ricovero e Cura a Carattere Scientifico

Vehicle Technologies Office

Vita-Salute San Raffaele University

San Raffaele University of Rome

IRCCS Ospedale San Raffaele

Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele

University of Bologna

Inserm

Harvard University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Saccharomyces boulardii in maintenance treatment of Crohn's disease.

Digestive Diseases and Sciences (2000)

Mario Guslandi G. Mezzi M. Sorghi Pier Alberto Testoni

Saccharomyces boulardii

Transplant surgery

10.1023/a:1005588911207

Cite

Citations (700)

Omeprazole-induced changes in gastric mucus secretion.

PubMed (1992)

Mario Guslandi M. Franceschi L. Fanti Alessandro Pellegrini A. Tittobello

The influence of omeprazole treatment on gastric mucus secretion in man was examined in two separate studies. 24 outpatients with endoscopic duodenitis but normal gastric mucosa were treated under double-blind conditions with either omeprazole 20 mg o.m. or placebo for four weeks. Omeprazole was found to induce a significant reduction (p less than 0.001) in the amount of neutral and total mucoproteins into the gastric juice and in the viscous and protective properties of mucus as assessed by a Mucoprotective Index. In a subsequent study 12 omeprazole-treated patients were re-examined either 10 days (6 patients) or 15 days (6 patients) after the drug withdrawal. A trend towards normalization of mucus secretion was detectable already after 10 days, but only at 15 days did gastric mucus fully revert to normal. The results suggest that the decrease in the quantity and quality of mucus secretion observed with omeprazole is a transient phenomenon, secondary to the sustained acid suppression induced by the drug and clinically irrelevant.

Source

Cite

Citations (6)

Role of Probiotics in the Management of Pouchitis

Current Pharmaceutical Design (2014)

Mario Guslandi

The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition. A possible, safer therapeutic alternative is represented by probiotics. To date the controlled studies addressing the possible efficacy of probiotic agents in the treatment of active pouchitis are few and inconclusive. By contrast the prophylactic use of a probiotic mixture (VSL #3) appears to be able to prevent development of pouchitis. The most convincing results have been observed in the maintenance of remission, where the probiotic mixture has been found, in most of the performed controlled trials, significantly effective in preventing pouchitis recurrence. Keywords: Pouchitis, gut microbiota, antibiotics, probiotics.

Pouchitis

10.2174/13816128113196660724

Cite

Citations (3)

Role of Saccharomyces boulardii in the prevention of clinical relapses of Crohn's disease

Digestive and Liver Disease (2000)

Mario Guslandi G. Mezzi P. Viaggi Pier Alberto Testoni

Saccharomyces boulardii

10.1016/s1590-8658(00)80218-2

Cite

Citations (3)

Effect of a Gel Formulation of Sucralfate on Gastric Microcirculation

Journal of International Medical Research (1993)

Mario Guslandi M. Sorghi A. Foppa P C Braga A. Tittobello

Dyspeptic patients ( n = 12) with endoscopic signs of chronic gastritis were treated orally for 28 days with a new gel formulation of sucralfate at a dose of 1 g twice daily. Before and after treatment, gastric blood flow was assessed during endoscopy by means of laser Doppler flowmetry. The sucralfate gel promoted a significant increase ( P < 0.001) in blood perfusion in all patients, restoring normal levels of gastric microcirculation. The results are consistent with observations in animals, suggesting that the mechanisms responsible for the gastroprotective and therapeutic properties of sucralfate include enhancement of mucosal blood flow.

Sucralfate

10.1177/030006059302100105

Cite

Citations (2)

Lactose content of gastrointestinal drugs: does it matter?

Alimentary Pharmacology & Therapeutics (2009)

Mario Guslandi

Sirs, I read with interest the paper by Eadala et al.1 reporting the amount of lactose contained in oral medications commonly employed to treat gastrointestinal disorders. While it is certainly important to be aware that lactose is often present in a wide range of drugs in higher amounts than previously suspected, this finding should not be overemphasized. It is well known that most patients with lactose intolerance can ingest up to 10–12 g of lactose without experiencing symptoms.2, 3 Others consider the safety limit to be as low as 5 g.4 Whatever be the truth and allowing that a minority of subjects can be sensitive to even lower doses,5, 6 the amount of daily lactose intake calculated by Eadala et al in the examined medications is bound to be, with a few exceptions (such as lactulose and, possibly, budesonide and loperamide), clinically irrelevant. Moreover, a recent study has provided evidence that ingestion of 400 mg of lactose from oral medications does not cause a significant effect either on breath H2 excretion or on gastrointestinal symptoms.7 On the other hand, patients with irritable bowel syndrome (IBS) often ascribe bloating and diarrhoea to the ingestion of foods and drugs irrespectively of their possible lactose content. Caution should be exercised before concluding that lactose-free medications must be prescribed to patients with IBS or other intestinal disorders. Declaration of personal and funding interest: None.

Lactulose

Flatulence

Lactose Intolerance

Bloating

Loperamide

10.1111/j.1365-2036.2009.03980.x

Cite

Citations (4)

TOC

Gastrointestinal Endoscopy (2004)

B Petersen Alan Barkun Steven Carpenter Perapa Chotiprasidhi Ram Chuttani

10.1016/s0016-5107(04)02003-6

Cite

Citations (0)

Nonorthodox Therapeutic Practices in Inflammatory Bowel Disease

The American Journal of Gastroenterology (1999)

Mario Guslandi

1GI Unit, S. Raffaele Hospital Milan, Italy Reprint requests and correspondence: Mario Guslandi, MD, S, Raffaele Hospital, Gastroenterology Unit, Via Olgettina 60, Milan 20132, Italy Received Sep. 1, 1998; accepted Oct. 26, 1998.

Reprint

10.1111/j.1572-0241.1999.0854b.x

Cite

Citations (0)

Relapse of duodenal ulceration after cimetidine treatment.

BMJ (1978)

Mario Guslandi M Cambielli L. Bierti A. Tittobello

Cimetidine

10.1136/bmj.1.6114.718-a

Cite

Citations (16)

Helicobacter pylori seroprevalence in Crohn's disease: lack of influence by pharmacological treatment.

PubMed (2002)

Mario Guslandi Lorella Fanti P.A. Testoni

Helicobacter pylori infection has a low prevalence in Crohn's disease, possibly because of sulphasalazine therapy. We investigated Helicobacter pylori seroprevalence in patients with Crohn's disease never treated with sulphasalazine in order to assess the possible role of antibiotic treatment.Two groups of patients with Crohn's disease (group I: subjects treated with ciprofloxacin, metronidazole or both during the last six months; Group II: subjects who were not given antibiotics during the last six months) and a control group of 30 patients with irritable bowel syndrome were considered. IgG anti-H. pylori levels were measured in all patients.Serology was positive respectively in 16.6%, 13.3% and 36.6% of cases in the three groups.Our findings confirm the Helicobacter pylori infection is infrequent in Crohn's disease. Neither sulphasalazine nor antibiotics appear to play a role.

Seroprevalence

Helicobacter

Source

Cite

Citations (22)